



Blue Cross
Blue Shield
of Michigan

A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Provider alerts about drugs covered under the medical benefit

For Blue Cross and Blue Care Network Commercial

Revised June 2026

This document contains links to provider alerts about drugs covered under the medical benefit.

May 2026

- [Immgolis Intri IV to have a prior authorization and site of care requirement for most commercial members starting June 1](#)
- [Radiation oncology and radiopharmaceuticals to be managed through the Oncology Value Management program starting Sept. 1](#)
- [We're adding requirements for additional medical oncology drugs for most members starting Aug. 12](#)

April 2026

- [Otarmeni to require prior authorization for most members starting May 4 and July 1](#)
- [Ponlinsi and Wainua to have requirements for most commercial members starting April 27](#)
- [Avlayah IV and Kresladi IV to require prior authorization for most members starting April 6 and May 1](#)
- [Additional medical benefit drugs to require prior authorization for Blue Cross commercial URMBT members starting July 1](#)
- [Additional drugs to have a site-of-care requirement for most commercial and URMBT members starting July 1](#)

March 2026

- [Loargys to require prior authorization for most members starting March 9 and April 1](#)

February 2026

- [Additional drugs to have a site-of-care requirement for most commercial members starting June 1](#)
- [We're adding requirements for additional medical oncology drugs for most members starting May 13](#)

January 2026

- [Leqvio and Zusduri to have requirements for Blue Cross commercial URMBT members starting April 15](#)
- [Yartemlea IV to require prior authorization for most members starting Jan. 19 and Feb. 2](#)

December 2025



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Provider alerts about drugs covered under the medical benefit

For Blue Cross and Blue Care Network Commercial

Revised June 2026

- [Exdensur SC to require prior authorization for most members starting Jan. 7 and Feb. 2](#)
- [Boncrea SC, Nufymco and Oziltus SC to require prior authorization for most commercial members starting Jan. 7](#)
- [Waskyra to require prior authorization for most members starting Dec. 22 and Jan. 15](#)
- [Jubereq and Osvyrti to require prior authorization for most commercial members starting Dec. 15](#)
- [Stoboclo, Osenvelt and denosumab-bmwo \(unbranded\) to have a site-of-care requirement for most commercial members starting March 9](#)
- [Itvisma to require prior authorization for most members starting Dec. 8 and Jan. 15](#)
- [Emrelis, Gazyva and Jobevne to require prior authorization for URMBT members with Blue Cross commercial plans starting March 4](#)
- [We're adding requirements for additional medical oncology drugs for most members starting March 4](#)
- [Medical benefit drug prior authorization changes for FEP members with Blue Cross commercial plans starting Feb. 1](#)
- [Duopa, Onapgo and Vyalev will require prior authorization for most commercial members starting March 2](#)
- [Update: Qivigy and Eydenzelt to have requirements for most commercial members starting Oct. 20](#)

November 2025

- [Update: We're changing how we manage Simponi Aria for most commercial members, starting Feb. 1](#)
- [Update: We are changing how we manage Entyvio for most PPO, HMO commercial members, starting Jan. 1](#)

October 2025

- [We're changing how we manage Simponi Aria for most commercial members, starting Feb. 1](#)
- [Bkemv to have a site-of-care requirement for most commercial members starting Feb. 1](#)
- [Update: Qivigy and Eydenzelt to have requirements for most commercial members starting Oct. 20](#)
- [Enoby SC and Xtrenbo SC to require prior authorization for most commercial members starting Oct. 20](#)
- [Changes to preferred drug designations under the medical benefit for most members, starting Jan. 1](#)
- [Update: Fensolvi, Triptodur to have requirements for most commercial members, starting Jan. 1](#)
- [Iluvien, Retisert to require prior authorization, step therapy requirements for most commercial members, starting Jan. 1](#)
- [Update: Additional drugs to require prior authorization for Blue Cross commercial URMBT members starting Dec. 31](#)

September 2025



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Provider alerts about drugs covered under the medical benefit

For Blue Cross and Blue Care Network Commercial

Revised June 2026

- [We are changing how we manage Entyvio for most PPO, HMO commercial members, starting Jan. 1](#)
- [Aukelso and Bosaya to require prior authorization for most commercial members starting Sept. 29](#)
- [Starting Jan. 1, we'll change how we cover Rinvoq, Rinvoq LQ and Skyrizi on our Custom Select Drug List](#)
- [Bildyos SC and Bilprevda SC to require prior authorization for most commercial members starting Sept. 15](#)
- [Niktimvo to require prior authorization for Blue Cross commercial URMBT members starting Dec. 10](#)
- [Update: Osenvelt and Stoboclo will be the preferred denosumab biosimilar products for most commercial members starting Dec.15](#)

August 2025

- [Anktiva, Herceptin Hylecta and Onivyde will have step therapy requirements for most members starting Dec. 1](#)
- [Datroway to require prior authorization for most members starting Dec. 1](#)
- [Papzimeos to require prior authorization for most commercial members starting Aug. 28](#)
- [Additional drugs to require prior authorization for Blue Cross commercial URMBT members starting Nov. 12](#)

July 2025

- [Bkemv will be the preferred eculizumab product for commercial members starting Oct. 12](#)
- [Gammagard Liquid ERC to have requirements for most commercial members starting July 14](#)
- [Additional drugs to have requirements for Blue Cross commercial URMBT members starting Oct. 8](#)

June 2025

- [Starjemza to require prior authorization for most commercial members starting June 12](#)
- [Gamifant to require prior authorization for most members starting Sept. 3](#)

May 2025

- [We're changing how we manage self-administered hemophilia products for most Blue Cross, BCN commercial members, starting Sept. 1](#)
- [Starting Sept. 1, we'll change how we pay for certain medications for most Blue Cross, BCN commercial members](#)
- [Yesintek to have a site-of-care requirement for most commercial members starting Sept. 1](#)



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Provider alerts about drugs covered under the medical benefit

For Blue Cross and Blue Care Network Commercial

Revised June 2026

- [New and updated requirements for some medical benefit drugs for Blue Cross commercial URMBT members starting Aug. 20](#)
- [We're adding requirements for additional medical oncology drugs for most members starting Aug. 20](#)
- [Imaavy IV and Zevaskyn to require prior authorization for most members](#)
- [Additional drugs to require prior authorization for Blue Cross commercial URMBT members starting July 30](#)

April 2025

- [Update: Selarsdi to require prior authorization for most members](#)
- [Qfitlia SC and some denosumab products to require prior authorization for most commercial members for dates of service on or after April 11](#)

March 2025

- [Step therapy required for Keytruda and Opdivo for nasopharyngeal cancer for most members starting June 18](#)
- [Update: Omlyclo and omalizumab-igec require prior authorization for most commercial members for dates of service on or after March 27](#)
- [Encelto to require prior authorization for most members](#)
- [Denosumab-dssb SC, Osenvelt SC and Stoboclo SC to require prior authorization](#)
- [How we communicate medical policy changes for medical benefit drugs that require prior authorization for commercial members](#)

February 2025

- [Changes to the management of oncology medical benefit drugs starting June 1](#)
- [Update: Tyenne will be preferred tocilizumab biosimilar product for most commercial members, starting June 1](#)
- [Alyglo, Amtagvi and Loqtorzi to have requirements for Blue Cross commercial URMBT members starting June 1](#)
- [Xbryk and Ospomyv to require prior authorization for most commercial members starting Feb. 28](#)
- [Rebyota and Ryoncil will have additional requirements for most commercial members starting March 31](#)
- [Avtozma to require prior authorization for most commercial members starting Feb. 20](#)
- [Update: Piasky and Tremfya to have a site-of-care requirement for most commercial members starting June 1](#)

January 2025

- [We're changing how we manage Stelara and Stelara biosimilar therapies for most commercial members, starting April 1 and May 1](#)
- [Updated: Simlandi preferred adalimumab product for Blue Cross, BCN commercial members](#)



Blue Cross
Blue Shield
of Michigan

A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Provider alerts about drugs covered under the medical benefit

For Blue Cross and Blue Care Network Commercial

Revised June 2026

- [Additional drugs to have requirements for Blue Cross commercial URMBT members starting April 16](#)
- [Alhemo to require prior authorization for most commercial members starting Jan. 16](#)
- [Ryoncil to require prior authorization for most members](#)